CB Scientific, Inc. Concludes Its Annual Meeting of Stockholders
CB Scientific, Inc. Concludes Its Annual Meeting of Stockholders
Shareholders endorse name change to Cardiac Biotech Solutions, Inc. subject to regulatory approval
股東支持更名爲心臟生物技術解決方案有限公司,但須經監管部門批准
LAS VEGAS, NV / ACCESSWIRE / March 19, 2024 / CB Scientific, Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, announced today that the company successfully concluded its Annual Meeting of Stockholders ("Annual Meeting") on Thursday, March 14, 2024 as planned. Votes representing approximately 66.87% of the total eligible shares were counted, and each of the 4 proposals on the agenda passed by a wide margin. Efforts to implement certain matters including updating the Company's Bylaws and changing the name of the Company to Cardiac Biotech Solutions, Inc., are expected to commence immediately.
內華達州拉斯維加斯/ACCESSWIRE/2024年3月19日/無創動態心臟監護產品和服務的設計者、製造商和分銷商CB Scientific, Inc.(OTCQB: CBSC)(“CBSC” 或 “公司”)今天宣佈,該公司按計劃於2024年3月14日星期四成功結束了年度股東大會(“年會”)。計算了約佔合格股份總數66.87%的選票,議程上的4項提案均以大幅優勢獲得通過。實施某些事項的努力預計將立即開始,包括更新公司章程和將公司名稱改爲Cardaic Biotech Solutions, Inc.。
"We were pleased that an overwhelming majority of our shareholders exhibited ample trust and confidence in management's recommendations to vote accordingly," said Charles Martin, Chief Executive Officer of CB Scientific, Inc. "Each of these actions are intended to position the Company for future success, and we now plan to continue aggressively pursuing our previously stated business objectives without delay."
CB Scientific, Inc.首席執行官查爾斯·馬丁說:“我們很高興我們的絕大多數股東對管理層提出的相應投票建議表現出充足的信任和信心,所有這些行動都旨在爲公司未來的成功做好準備,我們現在計劃毫不拖延地繼續積極追求我們先前提出的業務目標。”
As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
隨着更多新進展的出現,CB Scientific, Inc.計劃通過新聞稿和監管文件及時發佈公告,以隨時向股東、行業參與者和公開市場通報情況。
About CB Scientific, Inc.
CB Scientific, Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provides improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
關於 CB Scientific, Inc.
CB Scientific, Inc. 通過其國際子公司在動態無創心臟監測領域提供創新的產品和服務。我們的心電圖 (EKG) 設備、基於雲的交互式採集軟件以及適用於 iOS 和 Android 平台的智能手機應用程序可提高面臨心律異常風險的患者的依從性,併爲醫生提供更準確的信息。
Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: investor@cbscientificinc.com
Follow CBSC: X, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
公司聯繫信息:
電話:(888) 225-0870
電子郵件:一般查詢:info@cbscientificinc.com
投資者查詢:investor@cbscientificinc.com
關注 CBSC:X、Facebook、Instagram、LinkedIn、YouTube 和新聞
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
本信息披露可能包含1995年《私人證券訴訟法》所涵蓋的前瞻性陳述。除其他外,這些前瞻性陳述涉及引入或增強我們的服務和產品的計劃和時機、有關未來市場狀況、供需狀況的陳述,以及本新聞稿中包含的非歷史事實、涉及風險和不確定性的其他預期、意圖和計劃。我們對未來收入的預期取決於我們開發和提供當今可能無法生產且符合既定規格的產品和服務的能力。在本新聞稿中使用時,“計劃”、“期望”、“相信” 和類似的表述通常表示前瞻性陳述。這些陳述反映了我們當前的預期。它們受到許多風險和不確定性的影響,包括但不限於技術變化和普遍市場的變化。本新聞稿包括1933年《證券法》第27A條和1934年《證券法》第27E條所指的前瞻性陳述。本新聞稿中包含的非歷史事實的陳述可能被視爲前瞻性陳述。提醒投資者,前瞻性陳述本質上是不確定的。由於某些風險和不確定性,包括但不限於獲得融資以及監管部門和股東批准預期行動的能力,實際業績和結果可能與本文的預測或建議存在重大差異。
SOURCE: CB Scientific, Inc.
資料來源:CB Scientific, Inc.